StockData
GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc. (GDRX) stock

GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 11/3037% below fair value
$3.47−0.04 (-1.14%)

Close on Nov 17, 2026Market cap $1.18BP/E 86.8Yield –

GoodRx operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

GoodRx's operating cash flow for the twelve months ending Jun 30, 2026 was $201.58M, up 5.8% year over year. For fiscal 2025 it was $167.90M, down 8.7% from the year before. The highest annual figure on record is $183.89M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$167.90M-8.7%
FY2024Dec 31, 2024$183.89M+33.0%
FY2023Dec 31, 2023$138.29M-5.8%
FY2022Dec 31, 2022$146.78M-17.9%
FY2021Dec 31, 2021$178.78M+36.1%
FY2020Dec 31, 2020$131.34M+57.7%
FY2019Dec 31, 2019$83.29M+84.0%
FY2018Dec 31, 2018$45.25M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$80.83M+63.0%
Q1 FY2026Mar 31, 2026$11.84M+25.8%
Q4 FY2025Dec 31, 2025$32.89M-26.5%
Q3 FY2025Sep 30, 2025$76.02M-12.5%
Q2 FY2025Jun 30, 2025$49.58M+411.1%
Q1 FY2025Mar 31, 2025$9.41M-77.9%
Q4 FY2024Dec 31, 2024$44.74M+182.0%
Q3 FY2024Sep 30, 2024$86.86M+44.1%
Q2 FY2024Jun 30, 2024$9.70M-67.5%
Q1 FY2024Mar 31, 2024$42.59M+31.9%
Q4 FY2023Dec 31, 2023$15.87M-50.2%
Q3 FY2023Sep 30, 2023$60.27M+78.7%
Q2 FY2023Jun 30, 2023$29.87M-41.5%
Q1 FY2023Mar 31, 2023$32.29M+7.2%
Q4 FY2022Dec 31, 2022$31.88M-36.0%
Q3 FY2022Sep 30, 2022$33.73M-30.5%
Q2 FY2022Jun 30, 2022$51.05M+46.2%
Q1 FY2022Mar 31, 2022$30.12M-33.8%
Q4 FY2021Dec 31, 2021$49.81M+235.4%
Q3 FY2021Sep 30, 2021$48.56M+48.6%
Q2 FY2021Jun 30, 2021$34.93M-8.6%
Q1 FY2021Mar 31, 2021$45.49M-0.2%
Q4 FY2020Dec 31, 2020$14.85M-10.1%
Q3 FY2020Sep 30, 2020$32.67M–
Q2 FY2020Jun 30, 2020$38.23M–
Q1 FY2020Mar 31, 2020$45.59M–
Q4 FY2019Dec 31, 2019$16.52M–

More GoodRx figures

See a number that looks wrong?